EGFR and lung cancer: Blocking the EGFR-PI3K-AKT-mTOR signaling pathway with pharmacological agents (MHY) partly, but not completely, prevented combination treatment-induced cell cycle arrest, suggesting that other potential mechanisms of action for inducing arrest might be involved, and further investigation concerning the role of this treatment in lung cancer is needed.